Mean Platelet Volume in Children with Familial Mediterranean Fever and the Relationship with Attack Status, Colchicine Treatment and Gene Mutation

Abstract

Increased mean platelet volume (MPV) is a manifestation of platelet functions and activation, and accepted as a prognostic biomarker in patients with cardiovascular disease. We aimed to investigate MPV levels in pediatric Famillial Mediterranean Fever (FMF) patients during the attack and attack-free periods, and the effect of colchicine treatment and presence of M694V mutation. Thirty-five pediatric patients with FMF and 38 age-sex-matched healty controls were enrolled retrospectively into the study. Of the patients 11 (31%) had an ongoing attack, and 24 (69%) were in attack-free period. 26 (74%) patients were receiving colchicine and 16 (45.7%) had M694V gene mutation. There was no significant difference in platelet (PLT) and MPV between patients and healthy controls (p=0.196 and p=0.167 respectively). Mean PLT and MPV values of the patients during attack and attack-free period were also not significantly different (p=0.355 and p=0.118 respectively). However, MPV levels during an FMF attack were non-significantly lower than healthy control group (p=0.08). PLT and MPV levels were higher in patients receiving colchicine but the differences were not significant (p=0.097 and p=0.446 respectively). Mean MPV value of the FMF patients with M694V mutation was not significantly different than controls (p=0.773). In conclusion, this study reveals that pediatric FMF patients have similar MPV levels with healthy individuals even in the presence of M694V mutation. MPV as an early atherosclerosis marker, is not significantly elevated in this patient cohort. Regular treatment with colchicine and younger age may have a role in non-impaired platelet activation in FMF patients

Keywords

• Familial Mediterranean fever, MEFV gene, Mean platelet volume, Colchicine

Mean Platelet Volume in Children with Familial Mediterranean Fever and the Relationship with Attack Status, Colchicine Treatment and Gene Mutation

Abstract

Artmış ortalama platelet hacmi (OPH) platelet fonksiyonları ve aktivasyonunun bir göstergesidir ve kardiovaskuler hastalalığı olanlar için bir prognostik faktor olarak kabul edilmektedir. Pediatrik Ailesel Akdeniz Ateşi (AAA) hastalarında OPH düzeylerinin atak sırasında ve atak dışı dönemde incelemeyi ve kolşisin tedavisi ile M694v mutasyonunun varlığının OPH üzerine etkisini incelemeyi amaçladık. Çalışmaya retrospektif olarak 35 pediatrik yaş grubu AAA hastası ile 38 yaş ve cinsiyet eşleştirilmiş sağlıklı control grubu alındı. Çalışmaya alınan hastaların 11’inde (%31) devam eden atak mevcut iken, 24’ü (%69) atak dışı dönemdeydi. 26 (%74) hasta kolşisin tedavisi alırken, 16 (%45.7) hasta M694V gen mutasyonu taşıyordu. Hastalar ile kontrol grubu arasında platelet ve OPH bakımından anlamlı farklılık yoktu. (sırasıyla p=0.196 ve p=0.167). Ortalama platelet sayısı ile OPH değerleri atak sırasında ve atak dışı dönemde de anlamlı farklılık göstermedi (sırasıyla p=0.355 ve p=0.118). Bununla birlikte, OPH düzeyleri AAA atağı sırasında sağlıklı kontrol grubuna göre anlamlı olmayan düzeyde daha düşüktü. (p=0.08). Kolşisin tedavisi alan hastalarda platelet ve OPH düzeyleri daha yüksek idi fakat istatistiksel olarak anlamdı düzeyde değildi. (p=0.097 ve p=0.446). M694V mutasyonu taşıyan AAA’li hastaların OPH düzeyi ortalaması kontrollerden farklı değildi (p=0.773). Sonuç olarak bu çalışma pediatrik AAA hastaları M694V mutasyonu varlığında dahi sağlıklı bireylerle benzer OPH düzeylerine sahip olduğunu göstermiştir. Atherosklerozun erken bir belirteci olarak OPH bu hasta kohortunda anlamlı düzeyde artış göstermemektedir. Düzenli kolşisin tedavisi ve genç yaş AAA hastalarında platelet aktivasyonunun sağlam kalmasında rol oynayabilir

Keywords

• Ailesel akdeniz ateşi, MEFV geni, ortalama platelet hacmi, kolşisin

References

1. Onen F. Familial Mediterranean fever. Rheumatol Int 2006;26:489–96.
2. Bagci S, Toy B, Tuzun A, Ates Y, Aslan M, Inal A, et al. Continuity of cytokine activation in patients with familial Mediterranean fever. Clin Rheumatol 2004;23:333-7.
3. Lachmann HJ, Sengul B, Yavuzsen TU, et al. Clinical and subclinical inflammation in patients with Familial Mediterranean Fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006;45:746–50.
4. Tunca M, Kırkali G, Soytürk M, Akar S, Pepys MB, Hawkins PN. Acute phase response and evolution of Familial Mediterranean Fever. Lancet 1999;353:1415
5. Yuksel S, Ayvazyan L, Gasparyan AY. Familial Mediterranean Fever as an emerging clinical model of atherogenesis as- sociated with low-grade ınflammation. Open Cardiovasc Med J 2010;4:51–6.
6. Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991;338:1409-11.
7. Bath P, Algert C, Chapman N, Neal B. PROGRESS Collaborative Group. Association of mean platelet vol- ume with risk of stroke among 3134 individuals with his- tory of cerebrovascular disease. Stroke 2004;35:622-6.
8. Toplak H, Wascher TC. Cardiovascular risk factors in obe- sity. Influence of weight reduction on platelet volume: Different effects of hypocaloric diet and a very low calo- riediet. Eur J Clin Invest 1994;24:778–80.

9. Pereg D, Berlin T, Mosseri M. Mean platelet volume on ad- mission correlates with impaired response to thromboly- sis in patients with ST-elevation myocardial infarction. Platelets 2010;21:117-21.
10. Yazici S, Yazici M, Erer B, et al. The platelet indices in pa- tients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelet 2010;21:122-5.
11. Canpolat F, Akpinar H, Eskioğlu F. Mean platelet vol- ume in psoriasis and psoriatic arthritis. Clin Rheumatol 2010;29:325-8.
12. Park Y, Schoene N, Haris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 2002;13:301–6.
13. Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010;8:148–56.
14. Martin JF, Trowbridge EA, Salmon G, Plumb J. The bio- logical significance of platelet volume: its relation- ship to bleeding time, thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983;32:443-60.
15. Caliskan M, Erdogan D, Gullu H, et al. Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis 2008;196:306-12.
16. Weyrich AS, Lindemann S, Zimmerman GA. The evolv- ing role of platelets in inflammation. J Thromb Haemost 2003;1:1897–905.
17. Caliskan M, Gullu H, Yilmaz S, et al. Impaired coronary microvascular function in familial Mediterranean fever. Atherosclerosis 2007;195:161–7.
18. Peru H, Altun B, Dogan M, et al. The evaluation of ca- rotid intima-media thickness in children with Familial Mediterranean Fever. Clin Rheumatol 2008;27:689–94.
19. Bilginer Y, Ozaltin F, Basaran C, et al. Evaluation of in- tima media thickness of the common and internal ca- rotid arteries with inflammatory markers in Familial Mediterranean Fever as possible predictors for athero- sclerosis. Rheumatol Int 2008;28:1211–6.
20. Ahsen A, Ulu MS, Yuksel S, et al. As a new inflammatory marker for Famillial Mediterranean Fever: Neutrophil-to- Lymphocyte ratio. Inflammation 2013;36(6):1357-62.
21. Makay B, Türkyilmaz Z, Unsal E. Mean platelet volume in children with familial Mediterranean fever. Clin Rheumatol 2009;28:975-8.
22. Abanonu GB, Daskin A, Akdogan MF, Uyar S, Demirtunc R. Mean platelet volume and β-thromboglobulin levels in familial mediterranean fever: Effect of colchicine use? Eur J Intern Med 2012;23:661-4.
23. Sahin S, Senel S, Ataseven H, Yalcin I. Does mean plate- let volume influence the attack or attack-free period in the patients with Familial Mediterranean fever? Platelets 2013;24:320-3.
24. Sneddon John M. Effect of mitosis inhibitors on blood platelet microtubules and aggregation. J Physiol 1971;214:145-58.
25. Menche D, Israel A, Karpatkin S. Effect of colhicine and D2O on platelet aggregation and release induced by cal- cium ionophore A23187. J Clin Invest 1980;66: 284–91.
26. Levy M, Eldor A, Zylber-Katz E, Eliakim M. The effect of long-term colchicine therapy in patients with recurrent polyserositis on the capacity of blood platelets to synthe- size thromboxane A2. Br J Clin Pharmacol 1983;16:191–4.